Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Creative Planning

Creative Planning increased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 46.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 157,630 shares of the company’s stock after acquiring an additional 49,871 shares during the period. Creative Planning’s holdings in Takeda Pharmaceutical were worth $2,242,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TAK. Exchange Traded Concepts LLC boosted its position in Takeda Pharmaceutical by 77.7% during the third quarter. Exchange Traded Concepts LLC now owns 63,471 shares of the company’s stock worth $903,000 after purchasing an additional 27,756 shares in the last quarter. Ritholtz Wealth Management boosted its position in Takeda Pharmaceutical by 11.7% during the third quarter. Ritholtz Wealth Management now owns 27,169 shares of the company’s stock worth $386,000 after purchasing an additional 2,850 shares in the last quarter. First Affirmative Financial Network purchased a new stake in Takeda Pharmaceutical during the third quarter worth $226,000. Hexagon Capital Partners LLC boosted its position in Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after purchasing an additional 1,129 shares in the last quarter. Finally, CWM LLC boosted its position in Takeda Pharmaceutical by 52.6% during the third quarter. CWM LLC now owns 6,835 shares of the company’s stock worth $97,000 after purchasing an additional 2,356 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Down 1.7 %

TAK opened at $13.57 on Monday. The business’s fifty day moving average is $14.58 and its two-hundred day moving average is $13.78. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. The company has a market cap of $42.95 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. Analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.58 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.